Amgen (NASDAQ: AMGN), a global leader in biotechnology,  announced a $900 million expansion of its state-of-the-art biomanufacturing facility in New Albany, Ohio. This significant investment will create 350 new jobs, bringing the total number of positions at the site to 750, and will increase Amgen’s total investment in Central Ohio to over $1.4 billion.

“Amgen has been a leading U.S.-based manufacturer of biologic medicines since 1988,” said Robert A. Bradway, chairman and chief executive officer at Amgen. “Today’s investment reinforces our ongoing commitment to expanding U.S. manufacturing and ensuring patients around the world have access to our innovative medicines. Ohio offers a supportive business climate, skilled workforce, and strategic location, making it an ideal choice for this next phase of our investment.”

The expansion will add approximately 418,000 square feet to the existing facility, which opened in early 2024. The new construction is expected to be completed by 2027 and will enhance Amgen’s ability to meet growing demand for its medicines. 

“Ohio has built a strong foundation for economic development, which has led companies like Amgen to see Ohio as a premier destination for growth,” said Ohio Governor Mike DeWine. “We are happy to see Amgen deepen its commitment to our state and look forward to the innovation and economic impact it will drive.”

Since the passage of the Tax Cuts and Jobs Act of 2017, Amgen has invested nearly $5 billion in direct capital expenditures in the United States, generating an estimated $12 billion in additional economic output.